Michael Castagna
Chief Executive Officer chez MANNKIND CORPORATION
Fortune : 6 M $ au 31/03/2024
Profil
Michael E.
Castagna is currently the Chief Executive Officer & Director at MannKind Corp.
He is also a Director at Pet Partners.
Previously, he held positions as the Executive Director-Immunology Franchise at Bristol Myers Squibb Co. from 2010 to 2012, Director at Pharmasset, Inc. in 2005-2006, Vice President-Global Commercial at Amgen, Inc. from 2012 to 2016, and Vice President & Head-Biopharmaceuticals at Sandoz, Inc. from 2009 to 2010.
He also served as the VP & Head-North America Biopharmaceuticals at Novartis AG.
Dr. Castagna obtained a doctorate degree from Massachusetts College of Pharmacy & Health Science in 2014, an MBA from The Wharton School of the University of Pennsylvania in 2005, and an undergraduate degree from Philadelphia College of Pharmacy in 2000.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MANNKIND CORPORATION
0,46% | 21/03/2024 | 1 251 317 ( 0,46% ) | 6 M $ | 31/03/2024 |
Postes actifs de Michael Castagna
| Sociétés | Poste | Début |
|---|---|---|
| MANNKIND CORPORATION | Chief Executive Officer | 25/05/2017 |
| Pet Partners | Director/Board Member | - |
Anciens postes connus de Michael Castagna
| Sociétés | Poste | Fin |
|---|---|---|
| AMGEN INC. | Corporate Officer/Principal | 14/03/2016 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2012 |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | 01/11/2010 |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Director/Board Member | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Formation de Michael Castagna
| Massachusetts College of Pharmacy & Health Science | Doctorate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Philadelphia College of Pharmacy | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| MANNKIND CORPORATION | Health Technology |
| NOVARTIS AG | Health Technology |
| Entreprise privées | 3 |
|---|---|
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Health Technology |
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
| Pet Partners |
